Effects of Livagen peptide on chromatin activation in lymphocytes from old people
Efeitos do peptídeo Livagen na ativação da cromatina em linfócitos de idosos
Khavinson VKh, Lezhava TA, Monaselidze JG, Dzhokhadze TA, Dvalishvili NA, Bablishvili NK, Ryadnova IYu
Bull Exp Biol Med
Summary
This study investigated the effects of the tetrapeptide Livagen (Lys-Glu-Asp-Ala) on chromatin organization in lymphocytes obtained from elderly individuals (65-80 years). The research used chromosome banding techniques and ribosomal gene activity analysis to evaluate changes in chromatin structure after peptide treatment.
The results demonstrated that Livagen produced notable effects on aged chromatin:
- Activation of ribosomal genes (nucleolar organizing regions) that had been silenced
- Decondensation of heterochromatin — both constitutive and facultative
- Release of repressed genes in specific chromosomal regions (chromosomes 1, 13, 16)
- Increased global transcriptional activity
The observed de-heterochromatinization is particularly significant because heterochromatin accumulation is one of the most consistent epigenetic hallmarks of cellular aging. With advancing age, increasing segments of the genome become transcriptionally silent, contributing to functional decline of cells.
The authors, led by Prof. Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology, proposed that short peptides like Livagen can function as epigenetic bioregulators, capable of partially reversing age-associated chromosomal changes. This concept underpins the Russian approach of "peptide bioregulation" for anti-aging interventions.
Related Peptide
Livagen
Peptídeo hepático
Hepatic bioregulatory tetrapeptide developed by the Khavinson group. Regulates gene expression in hepatocytes and supports liver function, including detoxification processes. Used in short cycles for hepatic protection and regeneration.